Up to 31% Less Weight: Tirepatide’s 3-Year Impact
- MÁLAGA,Spain (AP) — Tirzepatide,marketed as Mounjaro in Europe,has proven effective in reducing weight among individuals with overweight or obesity but without diabetes,according to a new...
- The research,led by Luca Busetto of the University of Padua in collaboration with Eli Lilly,the manufacturer of Mounjaro,involved approximately 700 participants.
- After three years, average weight loss ranged from 10% to 31% of initial body weight, depending on the dosage group.
Tirzepatide Demonstrates Important Weight Loss in overweight,Obese Adults
Table of Contents
MÁLAGA,Spain (AP) — Tirzepatide,marketed as Mounjaro in Europe,has proven effective in reducing weight among individuals with overweight or obesity but without diabetes,according to a new study. The findings,stemming from a long-term evaluation of the SURMOUNT-1 trial,are scheduled for presentation in mid-May at the European Obesity Congress (ECO) 2025.
Study Details and Participant demographics
The research,led by Luca Busetto of the University of Padua in collaboration with Eli Lilly,the manufacturer of Mounjaro,involved approximately 700 participants. All participants had a body mass index (BMI) exceeding 27, indicating overweight or obesity. Participants received weekly doses of tirzepatide at varying levels: 5 mg, 10 mg, or 15 mg. Researchers monitored the degree of weight loss and the point at wich weight stabilized for each participant.
Weight Loss results and Stabilization
After three years, average weight loss ranged from 10% to 31% of initial body weight, depending on the dosage group. The study indicated that women and individuals without pre-existing obesity-related conditions, such as high blood pressure or lipid metabolism disorders, showed notably positive responses to the treatment. Most participants experienced a weight stabilization, or plateau, between weeks 24 and 48 of treatment, maintaining this weight with consistent medication.
Weight Loss Plateaus and Hormonal Factors
“At some point, every person encounters a weight loss plateau, regardless of which measures they take to accept weight,” said Dr.Busetto. He added, “GLP-1 and GIP are only two out of eight hormones that control hunger and weight, and finally the other hormones signal changes to the bodyS protective mechanisms to prevent changes to prevent further weight loss.”
Concerns About long-Term Effects
The study did not assess weight changes after cessation of tirzepatide treatment. Previous research suggests that the effects may not be sustainable long-term.Haiko Schlögl, who leads a new obesity study program at Leipzig University Clinic, expressed concern about the limited understanding of the medication’s long-term impact. speaking to MDR Sachsen, Schlögl stated, ”But what you know is that the therapy only works as long as you splash the medication.”
# Tirzepatide for Weight Loss: Your Questions Answered
Here’s a thorough guide to what you need to know about tirzepatide and its effects on weight loss, based on the latest study findings.
## What is tirzepatide?
Tirzepatide is a medication being explored for its effects on weight loss. In Europe, it’s marketed under the name Mounjaro. The study discussed in this article focuses on its impact on individuals struggling with overweight or obesity.
## How Does Tirzepatide work?
The provided text doesn’t go into the specific mechanisms of how tirzepatide works. However, we know it has shown effectiveness in weight reduction.
## What Does the Study on Tirzepatide show?
According to the study, which is a long-term evaluation of the SURMOUNT-1 trial, tirzepatide has proven effective in reducing weight among individuals with overweight or obesity but without diabetes. The findings are scheduled to be presented at the European Obesity Congress (ECO) in 2025.
## Who Participated in the study?
Approximately 700 individuals participated in the research, which was led by Luca Busetto of the University of padua and was conducted in collaboration with Eli Lilly, the manufacturer of Mounjaro. All participants had a body mass index (BMI) exceeding 27, indicating they were either overweight or obese.
## What Were the Dosage Levels Used?
Study participants received weekly doses of tirzepatide at three diffrent levels:
* 5 mg
* 10 mg
* 15 mg
## How Much Weight Did People Lose?
After three years, the average weight loss varied depending on the dosage group. The study found weight loss ranging from 10% to 31% of the participants’ initial body weight.
## When Did Weight Stabilization Occur?
Most participants experienced weight stabilization, or a plateau, between weeks 24 and 48 of treatment. This means their weight remained relatively stable while they continued receiving the medication.
## Were there Differences in Weight Loss Based on Demographics?
Yes, the study indicated that women and individuals without pre-existing obesity-related conditions, such as high blood pressure or lipid metabolism disorders, showed notably positive responses to the treatment.
## What Are Weight Loss Plateaus?
A weight loss plateau is a point where weight loss stops, even if someone continues with the same weight loss strategies. Dr. Busetto noted that everyone encounters thes plateaus, nonetheless of the measures they take.
## What Hormones Affect Weight Loss?
Dr. Busetto explained that GLP-1 and GIP are just two of eight hormones that control hunger and weight. Other hormones trigger the body’s protective mechanisms that prevent further weight loss.
## What About the Long-Term Effects of Tirzepatide?
The study did not assess weight changes after the cessation of tirzepatide treatment. previous research suggests that the effects of the medication may not be enduring long-term.
## What are the Concerns about the Long-Term Effects?
Haiko Schlögl, who leads a new obesity study program at Leipzig University Clinic, expressed concern about the limited understanding of the medication’s long-term impact. He stated that the therapy only works as long as the medication is being used.
## Summary of Key Findings
Here’s a table summarizing the key findings of the study:
| Aspect | Details |
|---|---|
| Medication | Tirzepatide (Mounjaro in Europe) |
| Study participants | Approximately 700 overweight or obese individuals (BMI > 27) |
| Dosage Levels | 5 mg, 10 mg, 15 mg weekly |
| Average Weight Loss (After 3 Years) | 10% to 31% of initial body weight |
| Weight Stabilization | Most participants experienced a plateau between weeks 24 and 48 |
| Noteworthy Responses | Women and individuals without obesity-related conditions had positive responses |
| long-Term Concerns | Effects may not be sustainable after stopping medication |